OKYO Pharma Limited (LSE:OKYO, OCTQB:EMMLF) is a biopharmaceutical company developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and ocular pain. Our goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and we achieve this through our collaboration with pioneer scientists in the field
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.